Access the full text.
Sign up today, get DeepDyve free for 14 days.
Xiao-Hui Zhang, L. Tee, Xiaogang Wang, Qunshan Huang, Shihua Yang (2015)
Off-target Effects in CRISPR/Cas9-mediated Genome EngineeringMolecular Therapy. Nucleic Acids, 4
L. Chicaybam, Andressa Sodré, B. Curzio, M. Bonamino (2013)
An Efficient Low Cost Method for Gene Transfer to T LymphocytesPLoS ONE, 8
( Kosicki M , Tomberg K , Bradley A . Repair of double‐strand breaks induced by CRISPR‐Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol 2018; 36: 765–771.30010673)
Kosicki M , Tomberg K , Bradley A . Repair of double‐strand breaks induced by CRISPR‐Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol 2018; 36: 765–771.30010673Kosicki M , Tomberg K , Bradley A . Repair of double‐strand breaks induced by CRISPR‐Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol 2018; 36: 765–771.30010673, Kosicki M , Tomberg K , Bradley A . Repair of double‐strand breaks induced by CRISPR‐Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol 2018; 36: 765–771.30010673
(2015)
Chapter 10 Translocation Detection Using Next-Generation Sequencing
( Zhang XH , Tee LY , Wang XG , Huang QS , Yang SH . Off‐target effects in CRISPR/Cas9‐mediated genome engineering. Mol Ther Nucleic Acids 2015; 4: e264.26575098)
Zhang XH , Tee LY , Wang XG , Huang QS , Yang SH . Off‐target effects in CRISPR/Cas9‐mediated genome engineering. Mol Ther Nucleic Acids 2015; 4: e264.26575098Zhang XH , Tee LY , Wang XG , Huang QS , Yang SH . Off‐target effects in CRISPR/Cas9‐mediated genome engineering. Mol Ther Nucleic Acids 2015; 4: e264.26575098, Zhang XH , Tee LY , Wang XG , Huang QS , Yang SH . Off‐target effects in CRISPR/Cas9‐mediated genome engineering. Mol Ther Nucleic Acids 2015; 4: e264.26575098
Mark Osborn, Beau Webber, Friederike Knipping, Cara-Lin Lonetree, N. Tennis, A. DeFeo, A. McElroy, Colby Starker, Catherine Lee, Sarah Merkel, T. Lund, K. Kelly-Spratt, M. Jensen, D. Voytas, C. Kalle, M. Schmidt, Richard Gabriel, K. Hippen, Jeffrey Miller, A. Scharenberg, J. Tolar, B. Blazar (2016)
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.Molecular therapy : the journal of the American Society of Gene Therapy, 24 3
Friederike Knipping, Mark Osborn, Karl Petri, J. Tolar, H. Glimm, C. Kalle, M. Schmidt, Richard Gabriel (2017)
Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor ModificationMolecular Therapy. Methods & Clinical Development, 4
H Abel, J Pfeifer, E Duncavage (2015)
Clinical Genomics
Thomas Müller, S. Jarosch, Monika Hammel, Justin Leube, S. Grassmann, Bettina Bernard, Manuel Effenberger, Immanuel Andrä, M. Chaudhry, Theresa Käuferle, A. Malo, L. Čičin-Šain, P. Steinberger, T. Feuchtinger, U. Protzer, Kathrin Schumann, M. Neuenhahn, Kilian Schober, D. Busch (2020)
Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapyCell Reports Medicine, 2
J. Yee (2016)
Off‐target effects of engineered nucleasesThe FEBS Journal, 283
( Bonini C , Mondino A . Adoptive T‐cell therapy for cancer: the era of engineered T cells. Eur J Immunol 2015; 45: 2457–2469.26202766)
Bonini C , Mondino A . Adoptive T‐cell therapy for cancer: the era of engineered T cells. Eur J Immunol 2015; 45: 2457–2469.26202766Bonini C , Mondino A . Adoptive T‐cell therapy for cancer: the era of engineered T cells. Eur J Immunol 2015; 45: 2457–2469.26202766, Bonini C , Mondino A . Adoptive T‐cell therapy for cancer: the era of engineered T cells. Eur J Immunol 2015; 45: 2457–2469.26202766
M. Sadelain, I. Rivière, S. Riddell (2017)
Therapeutic T cell engineeringNature, 545
Kilian Schober, Thomas Müller, Füsun Gökmen, S. Grassmann, Manuel Effenberger, M. Poltorak, Christian Stemberger, Kathrin Schumann, Theodore Roth, A. Marson, D. Busch (2019)
Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell functionNature Biomedical Engineering, 3
E. Brinkman, Tao Chen, Mario Amendola, B. Steensel (2014)
Easy quantitative assessment of genome editing by sequence trace decompositionNucleic Acids Research, 42
( Eyquem J , Mansilla‐Soto J , Giavridis T et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543: 113–117.28225754)
Eyquem J , Mansilla‐Soto J , Giavridis T et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543: 113–117.28225754Eyquem J , Mansilla‐Soto J , Giavridis T et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543: 113–117.28225754, Eyquem J , Mansilla‐Soto J , Giavridis T et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543: 113–117.28225754
( Berdien B , Reinhard H , Meyer S et al. Influenza virus‐specific TCR‐transduced T cells as a model for adoptive immunotherapy. Hum Vaccin Immunother 2013; 9: 1205–1216.23428899)
Berdien B , Reinhard H , Meyer S et al. Influenza virus‐specific TCR‐transduced T cells as a model for adoptive immunotherapy. Hum Vaccin Immunother 2013; 9: 1205–1216.23428899Berdien B , Reinhard H , Meyer S et al. Influenza virus‐specific TCR‐transduced T cells as a model for adoptive immunotherapy. Hum Vaccin Immunother 2013; 9: 1205–1216.23428899, Berdien B , Reinhard H , Meyer S et al. Influenza virus‐specific TCR‐transduced T cells as a model for adoptive immunotherapy. Hum Vaccin Immunother 2013; 9: 1205–1216.23428899
S. Tsai, Zongli Zheng, Nhu Nguyen, M. Liebers, V. Topkar, V. Thapar, Nicolas Wyvekens, Cyd Khayter, A. Iafrate, Long Le, Martin Aryee, J. Joung (2014)
GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleasesNature biotechnology, 33
Rahul Satija (2018)
Erratum: Strength in numbers from integrated single-cell neuroscienceNature Biotechnology, 36
( Zischewski J , Fischer R , Bortesi L . Detection of on‐target and off‐target mutations generated by CRISPR/Cas9 and other sequence‐specific nucleases. Biotechnol Adv 2017; 35: 95–104.28011075)
Zischewski J , Fischer R , Bortesi L . Detection of on‐target and off‐target mutations generated by CRISPR/Cas9 and other sequence‐specific nucleases. Biotechnol Adv 2017; 35: 95–104.28011075Zischewski J , Fischer R , Bortesi L . Detection of on‐target and off‐target mutations generated by CRISPR/Cas9 and other sequence‐specific nucleases. Biotechnol Adv 2017; 35: 95–104.28011075, Zischewski J , Fischer R , Bortesi L . Detection of on‐target and off‐target mutations generated by CRISPR/Cas9 and other sequence‐specific nucleases. Biotechnol Adv 2017; 35: 95–104.28011075
( van Loenen MM , Hagedoorn RS , de Boer R , van Egmond EH , Falkenburg JH , Heemskerk MH . Rapid re‐expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen‐specific stimulation. J Immunother 2011; 34: 165–174.21304404)
van Loenen MM , Hagedoorn RS , de Boer R , van Egmond EH , Falkenburg JH , Heemskerk MH . Rapid re‐expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen‐specific stimulation. J Immunother 2011; 34: 165–174.21304404van Loenen MM , Hagedoorn RS , de Boer R , van Egmond EH , Falkenburg JH , Heemskerk MH . Rapid re‐expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen‐specific stimulation. J Immunother 2011; 34: 165–174.21304404, van Loenen MM , Hagedoorn RS , de Boer R , van Egmond EH , Falkenburg JH , Heemskerk MH . Rapid re‐expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen‐specific stimulation. J Immunother 2011; 34: 165–174.21304404
( Tsai SQ , Zheng Z , Nguyen NT et al. GUIDE‐seq enables genome‐wide profiling of off‐target cleavage by CRISPR‐Cas nucleases. Nat Biotechnol 2015; 33: 187–197.25513782)
Tsai SQ , Zheng Z , Nguyen NT et al. GUIDE‐seq enables genome‐wide profiling of off‐target cleavage by CRISPR‐Cas nucleases. Nat Biotechnol 2015; 33: 187–197.25513782Tsai SQ , Zheng Z , Nguyen NT et al. GUIDE‐seq enables genome‐wide profiling of off‐target cleavage by CRISPR‐Cas nucleases. Nat Biotechnol 2015; 33: 187–197.25513782, Tsai SQ , Zheng Z , Nguyen NT et al. GUIDE‐seq enables genome‐wide profiling of off‐target cleavage by CRISPR‐Cas nucleases. Nat Biotechnol 2015; 33: 187–197.25513782
James Robinson, H. Thorvaldsdóttir, W. Winckler, M. Guttman, E. Lander, G. Getz, J. Mesirov (2011)
Integrative Genomics ViewerNature biotechnology, 29
J. Feucht, K. Opherk, P. Lang, S. Kayser, L. Hartl, W. Bethge, S. Matthes‐Martin, P. Bader, M. Albert, B. Maecker-Kolhoff, J. Greil, H. Einsele, P. Schlegel, F. Schuster, B. Kremens, C. Rossig, B. Gruhn, R. Handgretinger, T. Feuchtinger (2015)
Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT.Blood, 125 12
M. DePristo, E. Banks, R. Poplin, K. Garimella, J. Maguire, C. Hartl, A. Philippakis, G. Angel, M. Rivas, M. Hanna, A. McKenna, T. Fennell, A. Kernytsky, A. Sivachenko, K. Cibulskis, S. Gabriel, D. Altshuler, M. Daly (2011)
A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature genetics, 43
( Roth TL , Puig‐Saus C , Yu R et al. Reprogramming human T cell function and specificity with non‐viral genome targeting. Nature 2018; 559: 405–409.29995861)
Roth TL , Puig‐Saus C , Yu R et al. Reprogramming human T cell function and specificity with non‐viral genome targeting. Nature 2018; 559: 405–409.29995861Roth TL , Puig‐Saus C , Yu R et al. Reprogramming human T cell function and specificity with non‐viral genome targeting. Nature 2018; 559: 405–409.29995861, Roth TL , Puig‐Saus C , Yu R et al. Reprogramming human T cell function and specificity with non‐viral genome targeting. Nature 2018; 559: 405–409.29995861
A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, M. DePristo (2010)
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.Genome research, 20 9
( Knipping F , Osborn MJ , Petri K et al. Genome‐wide specificity of highly efficient TALENs and CRISPR/Cas9 for T cell receptor modification. Mol Ther Methods Clin Dev 2017; 4: 213–224.28345006)
Knipping F , Osborn MJ , Petri K et al. Genome‐wide specificity of highly efficient TALENs and CRISPR/Cas9 for T cell receptor modification. Mol Ther Methods Clin Dev 2017; 4: 213–224.28345006Knipping F , Osborn MJ , Petri K et al. Genome‐wide specificity of highly efficient TALENs and CRISPR/Cas9 for T cell receptor modification. Mol Ther Methods Clin Dev 2017; 4: 213–224.28345006, Knipping F , Osborn MJ , Petri K et al. Genome‐wide specificity of highly efficient TALENs and CRISPR/Cas9 for T cell receptor modification. Mol Ther Methods Clin Dev 2017; 4: 213–224.28345006
( Chicaybam L , Sodre AL , Curzio BA , Bonamino MH . An efficient low cost method for gene transfer to T lymphocytes. PLoS One 2013; 8: e60298.23555950)
Chicaybam L , Sodre AL , Curzio BA , Bonamino MH . An efficient low cost method for gene transfer to T lymphocytes. PLoS One 2013; 8: e60298.23555950Chicaybam L , Sodre AL , Curzio BA , Bonamino MH . An efficient low cost method for gene transfer to T lymphocytes. PLoS One 2013; 8: e60298.23555950, Chicaybam L , Sodre AL , Curzio BA , Bonamino MH . An efficient low cost method for gene transfer to T lymphocytes. PLoS One 2013; 8: e60298.23555950
( Sadelain M , Riviere I , Riddell S . Therapeutic T cell engineering. Nature 2017; 545: 423–431.28541315)
Sadelain M , Riviere I , Riddell S . Therapeutic T cell engineering. Nature 2017; 545: 423–431.28541315Sadelain M , Riviere I , Riddell S . Therapeutic T cell engineering. Nature 2017; 545: 423–431.28541315, Sadelain M , Riviere I , Riddell S . Therapeutic T cell engineering. Nature 2017; 545: 423–431.28541315
( Yee JK . Off‐target effects of engineered nucleases. FEBS J 2016; 283: 3239–3248.27208701)
Yee JK . Off‐target effects of engineered nucleases. FEBS J 2016; 283: 3239–3248.27208701Yee JK . Off‐target effects of engineered nucleases. FEBS J 2016; 283: 3239–3248.27208701, Yee JK . Off‐target effects of engineered nucleases. FEBS J 2016; 283: 3239–3248.27208701
( Kaeuferle T , Deisenberger L , Jablonowski L et al. CRISPR‐Cas9‐mediated glucocorticoid resistance in virus‐specific T cells for adoptive T cell therapy posttransplantation. Mol Ther 2020; 28: 1965–1973.32559432)
Kaeuferle T , Deisenberger L , Jablonowski L et al. CRISPR‐Cas9‐mediated glucocorticoid resistance in virus‐specific T cells for adoptive T cell therapy posttransplantation. Mol Ther 2020; 28: 1965–1973.32559432Kaeuferle T , Deisenberger L , Jablonowski L et al. CRISPR‐Cas9‐mediated glucocorticoid resistance in virus‐specific T cells for adoptive T cell therapy posttransplantation. Mol Ther 2020; 28: 1965–1973.32559432, Kaeuferle T , Deisenberger L , Jablonowski L et al. CRISPR‐Cas9‐mediated glucocorticoid resistance in virus‐specific T cells for adoptive T cell therapy posttransplantation. Mol Ther 2020; 28: 1965–1973.32559432
Jiangtao Ren, Xiaojun Liu, C. Fang, Shuguang Jiang, C. June, Yangbing Zhao (2016)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 InhibitionClinical Cancer Research, 23
( Wu X , Kriz AJ , Sharp PA . Target specificity of the CRISPR‐Cas9 system. Quant Biol 2014; 2: 59–70.25722925)
Wu X , Kriz AJ , Sharp PA . Target specificity of the CRISPR‐Cas9 system. Quant Biol 2014; 2: 59–70.25722925Wu X , Kriz AJ , Sharp PA . Target specificity of the CRISPR‐Cas9 system. Quant Biol 2014; 2: 59–70.25722925, Wu X , Kriz AJ , Sharp PA . Target specificity of the CRISPR‐Cas9 system. Quant Biol 2014; 2: 59–70.25722925
Justin Eyquem, J. Mansilla-Soto, Theodoros Giavridis, S. Stegen, Mohamad Hamieh, K. Cunanan, Ashlesha Odak, M. Gönen, M. Sadelain (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejectionNature, 543
( Schober K , Muller TR , Gokmen F et al. Orthotopic replacement of T‐cell receptor α‐ and β‐chains with preservation of near‐physiological T‐cell function. Nat Biomed Eng 2019; 3: 974–984.31182835)
Schober K , Muller TR , Gokmen F et al. Orthotopic replacement of T‐cell receptor α‐ and β‐chains with preservation of near‐physiological T‐cell function. Nat Biomed Eng 2019; 3: 974–984.31182835Schober K , Muller TR , Gokmen F et al. Orthotopic replacement of T‐cell receptor α‐ and β‐chains with preservation of near‐physiological T‐cell function. Nat Biomed Eng 2019; 3: 974–984.31182835, Schober K , Muller TR , Gokmen F et al. Orthotopic replacement of T‐cell receptor α‐ and β‐chains with preservation of near‐physiological T‐cell function. Nat Biomed Eng 2019; 3: 974–984.31182835
( Feucht J , Opherk K , Lang P et al. Adoptive T‐cell therapy with hexon‐specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125: 1986–1994.25617426)
Feucht J , Opherk K , Lang P et al. Adoptive T‐cell therapy with hexon‐specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125: 1986–1994.25617426Feucht J , Opherk K , Lang P et al. Adoptive T‐cell therapy with hexon‐specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125: 1986–1994.25617426, Feucht J , Opherk K , Lang P et al. Adoptive T‐cell therapy with hexon‐specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125: 1986–1994.25617426
Sangsu Bae, Jeongbin Park, Jin-Soo Kim (2014)
Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleasesBioinformatics, 30
Julia Zischewski, R. Fischer, L. Bortesi (2017)
Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases.Biotechnology advances, 35 1
( Muller TR , Jarosch S , Hammel M et al. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. Cell Rep Med 2021; 2: 100374.)
Muller TR , Jarosch S , Hammel M et al. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. Cell Rep Med 2021; 2: 100374.Muller TR , Jarosch S , Hammel M et al. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. Cell Rep Med 2021; 2: 100374., Muller TR , Jarosch S , Hammel M et al. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. Cell Rep Med 2021; 2: 100374.
Theodore Roth, C. Puig-Saus, Ruby Yu, Eric Shifrut, J. Carnevale, P. Li, J. Hiatt, Justin Saco, Paige Krystofinski, Han Li, Victoria Tobin, David Nguyen, Michael Lee, A. Putnam, A. Ferris, Jeff Chen, J. Schickel, Laurence Pellerin, D. Carmody, G. Alkorta-Aranburu, D. Gaudio, Hiroyuki Matsumoto, Montse Morell, Y. Mao, M. Cho, R. Quadros, C. Gurumurthy, Baz Smith, M. Haugwitz, S. Hughes, J. Weissman, Kathrin Schumann, Jonathan Esensten, Andy May, A. Ashworth, Gary Kupfer, S. Greeley, R. Bacchetta, E. Meffre, M. Roncarolo, N. Romberg, K. Herold, A. Ribas, M. Leonetti, A. Marson (2017)
Reprogramming human T cell function and specificity with non-viral genome targetingNature, 559
S. Tsai, J. Joung (2016)
Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleasesNature Reviews Genetics, 17
C. Bonini, A. Mondino (2015)
Adoptive T‐cell therapy for cancer: The era of engineered T cellsEuropean Journal of Immunology, 45
( Bae S , Park J , Kim JS . Cas‐OFFinder: a fast and versatile algorithm that searches for potential off‐target sites of Cas9 RNA‐guided endonucleases. Bioinformatics 2014; 30: 1473–1475.24463181)
Bae S , Park J , Kim JS . Cas‐OFFinder: a fast and versatile algorithm that searches for potential off‐target sites of Cas9 RNA‐guided endonucleases. Bioinformatics 2014; 30: 1473–1475.24463181Bae S , Park J , Kim JS . Cas‐OFFinder: a fast and versatile algorithm that searches for potential off‐target sites of Cas9 RNA‐guided endonucleases. Bioinformatics 2014; 30: 1473–1475.24463181, Bae S , Park J , Kim JS . Cas‐OFFinder: a fast and versatile algorithm that searches for potential off‐target sites of Cas9 RNA‐guided endonucleases. Bioinformatics 2014; 30: 1473–1475.24463181
( Stief TA , Kaeuferle T , Muller TR et al. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther 2022; 30: 198–208.34058386)
Stief TA , Kaeuferle T , Muller TR et al. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther 2022; 30: 198–208.34058386Stief TA , Kaeuferle T , Muller TR et al. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther 2022; 30: 198–208.34058386, Stief TA , Kaeuferle T , Muller TR et al. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther 2022; 30: 198–208.34058386
Theresa Kaeuferle, Larissa Deisenberger, Lena Jablonowski, Tanja Stief, Franziska Blaeschke, Semjon Willier, T. Feuchtinger (2020)
CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation.Molecular therapy : the journal of the American Society of Gene Therapy
(2011)
Rapid reexpression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulation
( Abel H , Pfeifer J , Duncavage E . Chapter 10 ‐ Translocation Detection Using Next‐Generation Sequencing. In: Kulkarni S , Pfeifer J eds. Clinical Genomics. Boston: Academic Press, 2015: 151–164.)
Abel H , Pfeifer J , Duncavage E . Chapter 10 ‐ Translocation Detection Using Next‐Generation Sequencing. In: Kulkarni S , Pfeifer J eds. Clinical Genomics. Boston: Academic Press, 2015: 151–164.Abel H , Pfeifer J , Duncavage E . Chapter 10 ‐ Translocation Detection Using Next‐Generation Sequencing. In: Kulkarni S , Pfeifer J eds. Clinical Genomics. Boston: Academic Press, 2015: 151–164., Abel H , Pfeifer J , Duncavage E . Chapter 10 ‐ Translocation Detection Using Next‐Generation Sequencing. In: Kulkarni S , Pfeifer J eds. Clinical Genomics. Boston: Academic Press, 2015: 151–164.
( Osborn MJ , Webber BR , Knipping F et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol Ther 2016; 24: 570–581.26502778)
Osborn MJ , Webber BR , Knipping F et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol Ther 2016; 24: 570–581.26502778Osborn MJ , Webber BR , Knipping F et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol Ther 2016; 24: 570–581.26502778, Osborn MJ , Webber BR , Knipping F et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol Ther 2016; 24: 570–581.26502778
B. Berdien, H. Reinhard, S. Meyer, Stefanie Spöck, N. Kröger, D. Atanackovic, B. Fehse (2013)
Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapyHuman Vaccines & Immunotherapeutics, 9
M Kosicki, K Tomberg, A Bradley (2018)
Repair of double‐strand breaks induced by CRISPR‐Cas9 leads to large deletions and complex rearrangements, 36
Tanja Stief, Theresa Kaeuferle, Thomas Müller, M. Döring, Lena Jablonowski, Kilian Schober, J. Feucht, K. Dennehy, Semjon Willier, Franziska Blaeschke, R. Handgretinger, P. Lang, D. Busch, T. Feuchtinger (2021)
Protective T-cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.Molecular therapy : the journal of the American Society of Gene Therapy
( Robinson JT , Thorvaldsdottir H , Winckler W et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24–26.21221095)
Robinson JT , Thorvaldsdottir H , Winckler W et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24–26.21221095Robinson JT , Thorvaldsdottir H , Winckler W et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24–26.21221095, Robinson JT , Thorvaldsdottir H , Winckler W et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24–26.21221095
C. June, Roddy O’Connor, O. Kawalekar, S. Ghassemi, M. Milone (2018)
CAR T cell immunotherapy for human cancerScience, 359
D. Stenger, Tanja Stief, Theresa Käuferle, Semjon Willier, F. Rataj, Kilian Schober, B. Vick, R. Lotfi, Beate Wagner, T. Grünewald, S. Kobold, D. Busch, I. Jeremias, Franziska Blaeschke, T. Feuchtinger (2020)
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.Blood
( Stenger D , Stief TA , Kaeuferle T et al. Endogenous TCR promotes in vivo persistence of CD19‐CAR‐T cells compared to a CRISPR/Cas9‐mediated TCR knockout CAR. Blood 2020; 136: 1407–1418.32483603)
Stenger D , Stief TA , Kaeuferle T et al. Endogenous TCR promotes in vivo persistence of CD19‐CAR‐T cells compared to a CRISPR/Cas9‐mediated TCR knockout CAR. Blood 2020; 136: 1407–1418.32483603Stenger D , Stief TA , Kaeuferle T et al. Endogenous TCR promotes in vivo persistence of CD19‐CAR‐T cells compared to a CRISPR/Cas9‐mediated TCR knockout CAR. Blood 2020; 136: 1407–1418.32483603, Stenger D , Stief TA , Kaeuferle T et al. Endogenous TCR promotes in vivo persistence of CD19‐CAR‐T cells compared to a CRISPR/Cas9‐mediated TCR knockout CAR. Blood 2020; 136: 1407–1418.32483603
Xuebing Wu, Andrea Kriz, P. Sharp (2014)
Target specificity of the CRISPR-Cas9 systemQuantitative Biology, 2
( McKenna A , Hanna M , Banks E et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next‐generation DNA sequencing data. Genome Res 2010; 20: 1297–1303.20644199)
McKenna A , Hanna M , Banks E et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next‐generation DNA sequencing data. Genome Res 2010; 20: 1297–1303.20644199McKenna A , Hanna M , Banks E et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next‐generation DNA sequencing data. Genome Res 2010; 20: 1297–1303.20644199, McKenna A , Hanna M , Banks E et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next‐generation DNA sequencing data. Genome Res 2010; 20: 1297–1303.20644199
( Brinkman EK , Chen T , Amendola M , van Steensel B . Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 2014; 42: e168.25300484)
Brinkman EK , Chen T , Amendola M , van Steensel B . Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 2014; 42: e168.25300484Brinkman EK , Chen T , Amendola M , van Steensel B . Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 2014; 42: e168.25300484, Brinkman EK , Chen T , Amendola M , van Steensel B . Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 2014; 42: e168.25300484
( June CH , O'Connor RS , Kawalekar OU , Ghassemi S , Milone MC . CAR T cell immunotherapy for human cancer. Science 2018; 359: 1361–1365.29567707)
June CH , O'Connor RS , Kawalekar OU , Ghassemi S , Milone MC . CAR T cell immunotherapy for human cancer. Science 2018; 359: 1361–1365.29567707June CH , O'Connor RS , Kawalekar OU , Ghassemi S , Milone MC . CAR T cell immunotherapy for human cancer. Science 2018; 359: 1361–1365.29567707, June CH , O'Connor RS , Kawalekar OU , Ghassemi S , Milone MC . CAR T cell immunotherapy for human cancer. Science 2018; 359: 1361–1365.29567707
( Ren J , Liu X , Fang C , Jiang S , June CH , Zhao Y . Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 2017; 23: 2255–2266.27815355)
Ren J , Liu X , Fang C , Jiang S , June CH , Zhao Y . Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 2017; 23: 2255–2266.27815355Ren J , Liu X , Fang C , Jiang S , June CH , Zhao Y . Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 2017; 23: 2255–2266.27815355, Ren J , Liu X , Fang C , Jiang S , June CH , Zhao Y . Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 2017; 23: 2255–2266.27815355
( DePristo MA , Banks E , Poplin R et al. A framework for variation discovery and genotyping using next‐generation DNA sequencing data. Nat Genet 2011; 43: 491–498.21478889)
DePristo MA , Banks E , Poplin R et al. A framework for variation discovery and genotyping using next‐generation DNA sequencing data. Nat Genet 2011; 43: 491–498.21478889DePristo MA , Banks E , Poplin R et al. A framework for variation discovery and genotyping using next‐generation DNA sequencing data. Nat Genet 2011; 43: 491–498.21478889, DePristo MA , Banks E , Poplin R et al. A framework for variation discovery and genotyping using next‐generation DNA sequencing data. Nat Genet 2011; 43: 491–498.21478889
Clinical & Translational Immunology – Wiley
Published: Jan 1, 2022
Keywords: CRISPR/Cas9; genetic engineering; off‐target; T‐cell receptor; T‐cell therapy; whole‐genome sequencing
You can share this free article with as many people as you like with the url below! We hope you enjoy this feature!
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.